LEADER 01351nam  2200373 a 450 
001 9910702850103321
005 20090615145241.0
035   $a(CKB)4970000000021331
035   $a(OCoLC)399813849
035   $a(EXLCZ)994970000000021331
100   $a20090615d2009      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aCounterdrug Technology Assessment Center$b[electronic resource] $eclarifying rationale for the research and development funding decisions would increase accountability /$f[Eileen R. Larence]
210  1$aWashington, DC :$cU.S. Govt. Accountability Office,$d[2009]
215   $a50 pages $cdigital, PDF file
300   $aTitle from title screen (viewed on June 3, 2009).
300   $a"March 12, 2009."
300   $a"GAO-09-339R."
320   $aIncludes bibliographical references.
517   $aCounterdrug Technology Assessment Center
606   $aDrug control$zUnited States$xFinance
615  0$aDrug control$xFinance.
700   $aLarence$b Eileen Regen$01384443
712 02$aUnited States.$bGovernment Accountability Office.
801  0$bGPO
801  1$bGPO
906   $aDOCUMENT
912   $a9910702850103321
996   $aCounterdrug Technology Assessment Center$93461653
997   $aUNINA